´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24
±³À°ÀÏÀÚ : 2024-05-24
±³À°Àå¼Ò : ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ 5Ãþ À̺¥Æ®È¦A+B ¿Ü 1°³·ë
±³À°ÁÖÁ¦ : ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑ¿µ»óÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ
´ã´çÀÚ : ÁÖÇýÁ¤
¿¬¶ôó : 02-465-9070
À̸ÞÀÏ : office@intervention.or.kr
±³À°Á¾·ù : ¿µ»óÀÇÇаú
Âü¼®¿¹»óÀÎ : 300¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 5 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í »çÀüµî·Ï-Á¤È¸¿ø50000¿ø, Àü¹®ÀÇ100000¿ø, Àü°øÀÇ(¿¬È¸ºñ³³ºÎÀÚ)¹«·á, Àü°øÀǹװøº¸ÀÇ 30000¿ø, ÁØȸ¿ø¹×±âŸ 50000¿ø/ÇöÀåµî·Ï-Á¤È¸¿ø70000¿ø, Àü¹®ÀÇ120000¿ø, Àü°øÀÇ(¿¬È¸ºñ³³ºÎÀÚ)¹«·á, Àü°øÀǹװøº¸ÀÇ 50000¿ø, ÁØȸ¿ø¹×±âŸ 70000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 12:50~13:00 Opening Remarks ()
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:00~13:15 ´ëÇ÷°ü ¼Õ»óÀÇ ÀÎÅͺ¥¼Ç ÃÖÅ¿ø(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:15~13:30 º¹ºÎ ¼Õ»óÀÇ ÀÎÅͺ¥¼Ç ¼»óÇö(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:30~13:45 °ñ¹Ý/¿äµµ ¼Õ»óÀÇ ÀÎÅͺ¥¼Ç ȲÁ¤ÇÑ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:45~14:00 ¿Ü»ó¿Ü°úÀÇ°¡ ¹Ù¶óº» ÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐÀÇ ÇöȲ°ú ¿ªÇÒ ¹ÚÂù¿ë(¼¿ïÀÇ´ë)
ÈÞ½Ä 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:00~14:20 Coffee break ()
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:20~14:35 Current status of anticancer agents for cTACE in Korea ÀÌÀÎÁØ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:35~14:50 Idarubicin: an alternative to dox in cTACE ÃÖÁø¿ì(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:50~15:05 Cisplatin-based cTACE ±èÁøÇü(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 15:05~15:20 The role of DEB-TACE and bland embolization as alternative to cTACE À̺´Âù(Àü³²ÀÇ´ë)
Åä·Ð 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 15:20~15:40 Panel discussion: Without Dox powder, what will be the approach for TACE? ()
ÈÞ½Ä 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 15:40~16:00 Coffee break ()
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 16:00~16:20 Biliary stone removal using balloon catheter, stone basket ±è¼öÈ£, À±Á¾Çõ(°¡Å縯ÀÇ´ë, °í½ÅÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 16:20~16:40 GB stone removal technical tips, Biliary stone removal using ERCP and SpyGlass ±è¿µÈ¯, ÀÌ»óÈÆ(°è¸íÀÇ´ë, °Ç±¹ÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 16:40~17:00 Biliary stone: surgical consideration À¯Áø¼ö(¼º±Õ°üÀÇ´ë)
ÈÞ½Ä 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 17:00~17:10 Coffee break ()
±âŸ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 17:10~17:20 What¡¯s new ()
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:20~14:32 (±¸¿¬¹ßÇ¥) Evaluation of patients undergoing Thoracic endovascular aortic repair for blunt thoracic aortic injury at a level 1 trauma center: Short term outcomes on left subclavian artery preservation with short proximal landing zones ±è¿ëÈÆ(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:32~14:44 (±¸¿¬¹ßÇ¥) Resorbable, Spherical Gelatin Particles versus Tris-Acryl Gelatin Microspheres for Uterine Artery Embolization: Randomized Controlled Trial ±è¸¸µæ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:44~14:56 (±¸¿¬¹ßÇ¥) The safety and efficacy of preoperative embolization in patients with bladder cancer, above T2 or VI-RADS 3 on CT and MRI: A Propensity Score-Matched Study ÀÌÈ£ÁØ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:56~15:08 (±¸¿¬¹ßÇ¥) Clinical factors associated with femoral artery pseudoaneurysm after femoral access for interventional procedures ½Åº´±Ç(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 15:08~15:20 (±¸¿¬¹ßÇ¥) Ultrasound-Guided Femoral Branch Block for Femoral Arterial Access in Endovascular Aneurysm Repair: A Study on Analgesic Efficacy and Safety Á¶¿µÁ¾(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 16:00~16:24 Diagnostic imaging of lymphatic disease: MR lymphangiography, CT lymphangiography Çã¼¼¹ü, ½ÅÁöÈÆ(¼¿ïÀÇ´ë, ¿ï»êÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 16:24~17:00 Treatment of chylothorax, traumatic chylous ascites, pelvic leaks and lymphoceles Çöµ¿È£, ±èÁø¿ì, ±è°æ¹Î(¼º±Õ°üÀÇ´ë, ¾ÆÁÖÀÇ´ë, ¿¬¼¼ÀÇ´ë)